Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: NTRK3

Gene summary for NTRK3

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

NTRK3

Gene ID

4916

Gene nameneurotrophic receptor tyrosine kinase 3
Gene AliasGP145-TrkC
Cytomap15q25.3
Gene Typeprotein-coding
GO ID

GO:0000165

UniProtAcc

Q96CY4


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
4916NTRK3PTC04HumanThyroidPTC2.66e-051.37e-010.1927
4916NTRK3ATC13HumanThyroidATC5.36e-551.40e+000.34
4916NTRK3ATC5HumanThyroidATC8.25e-731.46e+000.34
Page: 1 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0010563113ThyroidPTCnegative regulation of phosphorus metabolic process219/5968442/187234.47e-153.07e-13219
GO:0045936113ThyroidPTCnegative regulation of phosphate metabolic process218/5968441/187237.08e-154.75e-13218
GO:0032956113ThyroidPTCregulation of actin cytoskeleton organization182/5968358/187234.64e-142.79e-12182
GO:0032970113ThyroidPTCregulation of actin filament-based process197/5968397/187238.91e-144.89e-12197
GO:0001933113ThyroidPTCnegative regulation of protein phosphorylation173/5968342/187233.46e-131.75e-11173
GO:0042326113ThyroidPTCnegative regulation of phosphorylation189/5968385/187231.00e-124.64e-11189
GO:005149526ThyroidPTCpositive regulation of cytoskeleton organization121/5968226/187231.04e-114.27e-10121
GO:0031346110ThyroidPTCpositive regulation of cell projection organization173/5968353/187231.09e-114.40e-10173
GO:0048545113ThyroidPTCresponse to steroid hormone158/5968339/187238.10e-092.00e-07158
GO:0045860111ThyroidPTCpositive regulation of protein kinase activity176/5968386/187238.89e-092.17e-07176
GO:0071900110ThyroidPTCregulation of protein serine/threonine kinase activity164/5968359/187232.41e-085.43e-07164
GO:0010975110ThyroidPTCregulation of neuron projection development194/5968445/187231.05e-072.08e-06194
GO:003153220ThyroidPTCactin cytoskeleton reorganization60/5968107/187231.91e-073.51e-0660
GO:0033674111ThyroidPTCpositive regulation of kinase activity201/5968467/187231.95e-073.54e-06201
GO:001810518ThyroidPTCpeptidyl-serine phosphorylation143/5968315/187232.94e-075.04e-06143
GO:001820916ThyroidPTCpeptidyl-serine modification151/5968338/187234.61e-077.51e-06151
GO:0034329111ThyroidPTCcell junction assembly180/5968420/187231.17e-061.69e-05180
GO:005076716ThyroidPTCregulation of neurogenesis156/5968364/187235.86e-067.05e-05156
GO:190211516ThyroidPTCregulation of organelle assembly88/5968186/187237.41e-068.65e-0588
GO:007190210ThyroidPTCpositive regulation of protein serine/threonine kinase activity93/5968200/187231.01e-051.12e-0493
Page: 1 2 3 4 5 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
NTF3NTRK3NTF3_NTRK3NTEndometriumADJ
NTF3NTRK3NTF3_NTRK3NTEndometriumAEH
NTF3NTRK3NTF3_NTRK3NTLiverHealthy
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
NTRK3SNVMissense_Mutationnovelc.1106N>Ap.Thr369Asnp.T369NQ16288protein_codingdeleterious(0)probably_damaging(0.998)TCGA-AC-A5EH-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
NTRK3SNVMissense_Mutationnovelc.2258N>Gp.Val753Glyp.V753GQ16288protein_codingdeleterious(0)probably_damaging(0.995)TCGA-B6-A0IA-01Breastbreast invasive carcinomaFemale<65I/IIUnknownUnknownSD
NTRK3SNVMissense_Mutationc.1718C>Tp.Ala573Valp.A573VQ16288protein_codingtolerated(0.17)benign(0.088)TCGA-D8-A1XQ-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
NTRK3SNVMissense_Mutationc.917N>Cp.Arg306Prop.R306PQ16288protein_codingtolerated(0.23)benign(0.346)TCGA-E2-A14R-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapydoxorubicinPD
NTRK3SNVMissense_Mutationrs374759890c.1744C>Tp.Arg582Trpp.R582WQ16288protein_codingdeleterious(0)probably_damaging(0.999)TCGA-E2-A1B1-01Breastbreast invasive carcinomaFemale<65I/IIOther, specify in notesbiphosphonatezoledronicSD
NTRK3SNVMissense_Mutationc.2481N>Tp.Leu827Phep.L827FQ16288protein_codingdeleterious(0)benign(0.403)TCGA-GM-A2DM-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapytaxolCR
NTRK3insertionIn_Frame_Insnovelc.1745_1746insTCACATGTGGCTAGTTTTTACCATACAGGGAAGCACp.Arg582_Lys583insHisMetTrpLeuValPheThrIleGlnGlySerThrp.R582_K583insHMWLVFTIQGSTQ16288protein_codingTCGA-BH-A0AY-01Breastbreast invasive carcinomaFemale<65I/IIChemotherapySD
NTRK3SNVMissense_Mutationrs866711936c.364N>Ap.Ala122Thrp.A122TQ16288protein_codingdeleterious(0)probably_damaging(0.982)TCGA-2W-A8YY-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
NTRK3SNVMissense_Mutationnovelc.1636G>Ap.Glu546Lysp.E546KQ16288protein_codingdeleterious(0)probably_damaging(0.999)TCGA-C5-A1ME-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
NTRK3SNVMissense_Mutationc.485N>Cp.Phe162Serp.F162SQ16288protein_codingdeleterious(0)probably_damaging(0.942)TCGA-C5-A7CL-01Cervixcervical & endocervical cancerFemale<65III/IVChemotherapycisplatinPD
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMEinhibitor381744997REPOTRECTINIB
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMEinhibitor252827368PEXIDARTINIB
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMEMK-2461MK-2461
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMECyclopenta[d]pyrimidine derivative 1
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMESNS-314SNS-314
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMEILORASERTIBILORASERTIB
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMESB-202190SB-202190
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMEGW441756XGW441756X
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMEIFN15875206
4916NTRK3CLINICALLY ACTIONABLE, ENZYME, TYROSINE KINASE, KINASE, DRUG RESISTANCE, DRUGGABLE GENOMEREPOTRECTINIBREPOTRECTINIB30093503
Page: 1 2 3 4 5 6 7